Tumor Vaccine Group, Center for Translational Medicine in Women's Health, University of Washington, Seattle WA, USA.
Breast Cancer (Dove Med Press). 2010 Jun 4;2:25-36. doi: 10.2147/bctt.s6956.
Various human malignancies are immunogenic and recent cancer vaccine trials have demonstrated potential survival benefit. Breast cancer is immunogenic and there are several tumor associated antigens for which breast cancer vaccines have been developed. Breast cancer vaccines are designed to stimulate the immune response at various steps in the native antigen processing pathway for immunosurveillance. Human epidermal growth factor receptor 2 (HER-2/neu), mucin 1 (MUC-1), and human telomerase reverse transcriptase (hTERT) are some of the most studied antigens actively being targeted for vaccination in breast cancer patients. These vaccines are designed to elicit cytotoxic and/or helper T cell responses. Over the last several years, there has been reported progress in human clinical trials for these antigens. Cancer vaccines have repeatedly been shown to be safe with production of minimal toxicity. Recent clinical advances in the development of cancer vaccines demonstrate the potential clinical benefit that cancer vaccines hold.
多种人类恶性肿瘤具有免疫原性，最近的癌症疫苗试验已经证明了其具有潜在的生存获益。乳腺癌具有免疫原性，已经开发出了多种针对乳腺癌的肿瘤相关抗原疫苗。乳腺癌疫苗旨在刺激天然抗原处理途径中的免疫反应，以进行免疫监视。人类表皮生长因子受体 2（HER-2/neu）、黏蛋白 1（MUC-1）和人端粒酶逆转录酶（hTERT）是一些研究最多的抗原，目前正在针对乳腺癌患者进行疫苗接种。这些疫苗旨在引发细胞毒性和/或辅助性 T 细胞反应。在过去几年中，这些抗原的人体临床试验取得了一些进展。癌症疫苗已被证明是安全的，产生的毒性极小。癌症疫苗开发方面的最新临床进展表明，癌症疫苗具有潜在的临床获益。
